1st Group Enrolled in Trial of uniQure’s AMT-130 Gene Therapy

1st Group Enrolled in Trial of uniQure’s AMT-130 Gene Therapy

294472

1st Group Enrolled in Trial of uniQure’s AMT-130 Gene Therapy

uniQure has completed patient enrollment for the first group participating in a Phase 1/2 trial assessing the safety and efficacy of AMT-130, its experimental gene therapy for Huntington’s disease. “This is an important milestone in our ongoing clinical development of AMT-130,” David Cooper, MD, PhD, vice president of clinical development at uniQure, said in a press release. “Completing enrollment of the first, 10-patient cohort ahead of schedule highlights the high level of interest among the Huntington’s…

You must be logged in to read/download the full post.